The systemic inflammatory response index (SIRI) as a prognostic factor for long-term survival in patients with pancreatic cancer.

AIMS: Pancreatic cancer has a very poor prognosis and is a leading cause of cancer-related deaths. Our aim is to investigate the presence of novel prognostic markers in pancreatic cancer that are easy to calculate, inexpensive, non-invasive, and do not cause a loss of time.

METHODS

A total of 164 patients were included in the study. The demographic and clinical characteristics, laboratory findings, and radiological data of the patients were retrospectively reviewed using hospital records.

RESULTS

Of the patients, 112 (68.3%) were male, and the mean age of all patients was 63.29 ± 12.5 years. The one-,two-,and five-year survival rates of the patients were determined to be 43.9% (n = 72), 29.3% (n = 48), and 21.3% (n = 35), respectively. During the 1-,2, and 5-year follow-ups, the absence of surgery, advanced disease stage, and elevated systemic inflammation response index (SIRI) were identified as independent risk factors for increased mortality in pancreatic cancer. SIRI was found to be a prognostic factor influencing both short- and long-term survival in pancreatic cancer.

CONCLUSION

We found that SIRI is a stronger prognostic factor than the NLR, PIV, and SII indices in predicting survival in pancreatic cancer. Monitoring SIRI in pancreatic cancer may provide insight into the status of the local immune response and systemic inflammation, and help in estimating patient survival.